Figure 6. IL‐4 mediates eosinophil effects during resolution of inflammation.

• A
  IL‐4 levels in paws from naive and zymosan‐injected mice were determined by ELISA 8 and 24 h after injection of zymosan in paws of control or eosinophil‐depleted mice. Data are shown as mean ± SEM (n = 6 mice). Student's t‐test/two‐way ANOVA/Bonferroni, control vs. anti‐Siglec F antibody treatment: **P < 0.01, ***P < 0.001.
• B
  FACS analysis of the eosinophil number in paws from control and eosinophil‐depleted mice with or without IL‐4c treatment 24 h prior zymosan injection. Data are shown as the mean ± SEM (n = 8 mice). Two‐way ANOVA/Bonferroni ***P < 0.001.
• C
  Same as panel B except that resident (Ly6C⁻) and monocyte‐derived macrophages (Ly6C⁺) were determined.
• D–F
  Same as panel B except that M2‐like (panel D), M1‐like (panel E) and M0 macrophages (panel F) were determined. Data are shown as mean ± SEM (n = 8 mice). Student's t‐test/Two‐way ANOVA/Bonferroni, control vs. anti‐Siglec F antibody treatment: *P < 0.05, ***P < 0.001.

Source data are available online for this figure.